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Background: Pancreatic pseudocyst endoscopic drai-
nage has been described as a good treatment option,
with morbidity and mortality rates that are lower
than surgery. The aim of our study is to describe the
efficacy of different forms of endoscopic drainage
and estimate pseudocyst recurrence rate after short
follow up period.
Patients and Methods: We studied 30 patients with
pancreatic pseudocyst that presented some indica-
tion for treatment: persistent abdominal pain, infec-
tion or cholestasis. Clinical evaluation was per-
formed with a pain scale, 0 meaning absence of pain
and 4 meaning continuous pain. Pseudocysts were
first evaluated by abdominal CT scan, and after
endoscopic retrograde pancreatography the patients
were treated by transpapillary or transmural (cy-
stduodenostomy or cystgastrostomy) drainage. Pseu-
docyst resolution was documented by serial CT
scans.
Results: 25/30 patients could be treated. Drainage
was successful in 21 (70% in an ’intention to treat’
basis). After a mean follow-up of 42 4-35.82 weeks,
there was only I (4.2%) recurrence. A total of 6 com-
plications occurred in 37 procedures (16.2%), and all
but 2 were managed clinically and/or endoscopi-
cally: there was no mortality related to the proce-
dure. Patients submitted to combined drainage
needed more procedures than the other groups.
There was no difference in the efficacy when we
compared the three different drainage methods.
Conclusions: We concluded that pancreatic pseu-
docyst endoscopic drainage is possible in most
patients, with high success rate and low morbidity.
Keywords: Pancreatic pseudocyst, cystenterostomy, endo-
scopic drainage, plastic stents
INTRODUCTION
Pancreatic pseudocysts are collections of pan-
creatic juice, with high enzymatic concentration,
located inside or around the gland, formed as a
result of pancreatic inflammation and/or ductal
injury [1-3]. They are observed as a complica-
tion of acute pancreatitis (16% to 50%), or during
the course of chronic pancreatitis, in 20% to 40%
of the cases [4, 5].
Most of the pseudocysts secondary to acute
pancreatitis resolve spontaneously [6,7] while
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those associated with chronic, disease are asso-
ciated with a lower spontaneous resolution rate
and more complications [2,8]. Complications
include infection, rupture, haemorrhage, biliary
compression with or without jaundice, gastro-
intestinal obstruction, chronic pain, oesophageal
varices, leakage with ascites or pleural fluid and
pseudoaneurism [8-10].
Indications for drainage include: lesions larger
than 4cm or present longer than six weeks, persis-
tent pain, complications and increased volume
documented by imaging test [6, 7, 11].
Complications of surgical treatment occur in
10% to 30%, mortality in 1% to 5% and recur-
rence in 10% to 20% of the cases [9,12,13].
Percutaneous aspiration is a simple method
but associated with frequent recurrence [6, 14].
Percutaneous drainage guided by US or CT is
reserved for critically ill patients or for those
with infected pseudocyst [15].
Endoscopic drainage has been reported dur-
ing the last decade with success rates higher
than 80% and can be transmural (cystgastrost-
omy or cystduodenostomy) or transpapillary
[11, 12, 16, 17]. Both can be combined although
transpallary drainage should be the first option
because it’s probably associated with a lower
complication rate [18].
Endoscopic treatment is reported to have low-
er morbidity than surgery [5]. This study aimed
to evaluate effectiveness and complications of
pancreatic pseudocysts endoscopic drainage.
MATERIALS AND METHODS
Between June 1994 and May 1997, 30 patients
referred to our Unit for pancreatic pseudocyst
drainage were included in a prospective study.
Inclusion criteria were: pancreatic pseudocyst
confirmed by abdominal CT, more than 18 years
of age, presence of at least one indication for
drainage: pseudocyst larger than 4cm present
for at least 6 weeks with persistent abdominal
pain, progressive increase in size or complica-
tion (gastrointestinal or biliary obstruction,
infection). Severity of abdominal pain was
recorded before the drainage and at the end of
the study according to the following score: zero
(no pain), 1(sporadic episodes of pain), 2
(weekly episodes), 3 (daily attacks of pain).
Size, number, location and relationship of the
pseudocyst with the stomach or duodenum
were evaluated with CT scan. During endoscopy
we always attempted to identify any indentation
on gastric or duodenal wall possibly caused by
the pseudocyst. Retrograde endoscopic cholan-
giography was obtained whenever cholestasis
was present.
According to the findings during ERCP,
whenever possible, patients were submitted to
endoscopic treatment or referred to surgery.
Endoscopic drainage was performed in 4 differ-
ent ways, as follows:
Group I-transpapillary drainage (TP)- presence
of communication between the main pancreatic
duct (MPD) and the pseudocyst, and we were
able to cross any stricture and place a pancreatic
plastic stent.
Group II-cystgastrostomy (CG)-when transpa-
pillary drainage was not possible (absence of
communication between the pseudocyst and
MPD, or unable to access the MPD) and there
was a clear compression on the gastric wall, and
the distance between the pseudocyst and the
gastric wall was less than I cm measured by CT
scan.
Group III-cystduodenostomy (CD)-same as de-
scribed for cystgastrostomy but compression
was present on the duodenum.
Group IV-combined drainage (CB)-performed
whenever the pseudocyst did not heal after a
single drainage procedure.
Any treatment was repeated whenever neces-
sary. Transpapillary drainage was the first treat-
ment option. The distal end of the stent was
located in the MPD, not necessarily inside the
pseudocyst. In the presence of a MPD stricture
dilation was performed with a passage dilator
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ed proximally to the stricture. Transmural
drainage started with pseudocyst puncture
trough the gastric or duodenal wall with the tip
of a polipectomy snare. After spontaneous-drai-
nage of characteristic fluid, the snare was re-
moved and a guide wirewas passed into the snare
sheath; then a plastic stent was placed over the
wire. Straight or pigtail plastic stents (9 or 10 Fr)
were used for transmural drainage, and 5 or 7 Fr
plastic pancreatic stents were inserted in trans-
papillary drainage.
Abdominal pain and obstructive symptoms
were evaluated clinically and regression of the
pseudocyst was confirmed by CT. Once pseu-
docyst resolution was confirmed the stents were
removed and pancreatogram was done to look
for possible ductal lesions.
An intention to treat analysis was done to
evaluate our results. Statistical analysis were
done with Fisher test, Student "t" test, X2 and
Kruskal-Wallis, whenever appropriate.
RESULTS
Most of the patients (90%) were male and age
ranged from 24 to 64 years (x 38,46 + 9,87 years).
Pseudocyst aetiology was alcoholic chronic
pancreatitis (ACP) in 26/30 patients (86,7%),
abdominal trauma in 2/30 (6,7%) and 2/30 after
surgery (6,6%). Three patients with ACP
had a history of pseudocyst surgical treat-
ment. Persistent abdominal pain was the most
frequent drainage indication (93,4%).
Overall 38 pseudocysts was diagnosed: 24
patients with one lesion, 4 patients with 2 and 2
patient with 3. Pseudocyst size ranged from 2 to
20cm (x 9,14 + 4,93 cm), located in the body
(52,6%), head (31,6%) or tail (15,8%).
Indentation of the gastric or duodenal wall was
identified in 20/30 patients (66,7%), MPD stric-
ture and communication with the pseudocyst in
57,7% and 60% respectively. Fluid was studied in
17 patients and culture was positive in 6 (35%).
After ERCP, in 5/30 patients (16,7%) there
were no favourable conditions for endoscopic
drainage because there was no access to the
lesion (transpapillary or transmural). In the 25
remaining patients (83,3%) endoscopic drainage
was performed: 8 cases in Group I (ranspapil-
lary), 5 in Group II (cystgastrostomy), 7 in Group
III (cystduodenostomy) and 5 in Group IV
(combined drainage), total of 37 procedures (14
CG, 7 CD and 16 TP). The average number was
of 1.48 procedures per patient and Group IV had
more procedures compared with the other
groups (p 0,002).
Non-obstructed stents were removed after an
average of 59,10+28,41 days (range 27 to 120
days). Main pancreatic duct changes (irregula-
rities and strictures) were noted in 2 patients
after transpapillary drainage, both had resolu-
tion of the pseudocyst without recurrence.
Success (regression of the pseudocyst) was ob-
tained in 21/25 (84%) in a ’per protocol analysis’,
but a more realistic intention to treat analysis
showed that rate to be of 21/30 patients (70%).
Pseudocyst regression was different according
to drainage group. Better results occurred in
Group IV, although such difference was not
statistically significant (Tab. I).
Twenty one 21 patients were followed from 2
to 124 weeks (x 42 + 35,82 weeks) and recur-
rence was diagnosed in only one patient (4,8%),
12 months after CG. He was then submitted to
another CG guided by endoscopic ultrasound
and he is now asymptomatic. Only 4 patients are
taking non-opioid analgesic medication because
of abdominal pain, but with clinical score
improvement, and CT didn’t show pseudocyst
recurrence.
TABLE Success rate in the different drainage groups
Patient N Success rate (%)
Transpapillary 8 75
Cystgastrostomy 5 80
Cystduodenostomy 7 85
Combined 5 100
Analysis
for protocol 25 84
intention to treat 30 70336 E.D. LIBERA et al.
TABLE II Frequency of complications (%) in the different
groups
Drainage Complications %
Transpapillary pancreatitis 2.7
Cystgastrostomy stent proximal migration
bleeding* 5.4
Cystduodenostomy perforation duodenal* 2.7
Combined stent proximal migration
pneumoperitoneum 5.4
Total 16.2
referred to surgery.
Evaluation of abdominal pain in the end of the
follow up period identified 17 patients without
pain (score zero) and four patients with ACP still
complain of some pain. The average abdominal
pain score was 2.48 4-0.51 before and 0.28 4- 0,64
after treatment (p < 0,001, 95% CI: 1.83- 2.55).
We analysed in an univariate way some
factors that could be predictive of a good
endoscopic drainage result: gastroduodenal in-
dentation, MPD stricture, communication be-
tween the pseudocyst and MPD, age, size of the
pseudocyst, cholestasis, presence of multiple
lesions, pseudocyst larger than 6cm, serum
albumin <3,5 g/dl. Only the presence of gastro-
duodenal wall indentation seen at endoscopic
reached statistical significance (p 0,03).
The complications of the 37 procedures
occurred after CG (one case of each: bleeding,
asymptomatic pneumoperitoneum and proxi-
mal stent migration), TP (one case of each: mild
pancreatitis and proximal stent migration) and
CD (duodenal perforation in one case), total of
6/37 (16.2%) complications (Tab. II). Most com-
plications were benign and managed clinically
and/or endoscopically. Two patients (bleeding
and perforation) needed surgery (5,4%). There
was no mortality related to the procedure. There
was no difference between treatment Groups.
DISCUSSION
There is still a lot of controversy regarding
pancreatic pseudocysts treatment, and up to
now there is not an ideal way to treat them.
There is no consensus in the literature
regarding antibiotic use before pseudocyst en-
doscopic drainage. Some authors [11,13] recom-
mended its use while others [17,18] just
indicated it when there are evidences of pseu-
docyst infection. In this study we only pre-
scribed parenteral antibiotics when there were
clinical signs of infection and/or positive cul-
tures, or when we were not able to drain the
lesion or the bile duct (when biliary stricture was
present). Pseudocyst infection was not among
our complications. All 6 patients with a positive
pseudocyst fluid culture had resolution without
recurrence, and if drainage through the stent is
effective, pseudocyst infection doesn’t seem to
interfere with the result of endoscopic treatment,
as observed in this study.
Our findings during pancreatograms were
similar with those described earlier authors [4,
17,18].
Several complications of transpapillary drai-
nage have been described and they include: stent
occlusion (symptomatic or not), stent proximal or
distal migration, pseudocyst infection, pseudo-
cyst recurrence or worsening, pancreatitis, pan-
creatic ducts inflammatory changes and
duodenal erosions [12,19-21]. Stent removal or
exchange should be done within 4 to 6 weeks due
to high occlusion rate after this period [22], up to
100% after 9 weeks [23]. In our study 3 patients
needed stent exchange because of occlusion, but
none of them presented any symptoms and those
were not considered complications. One patient
had a transpapillary stent proximal migration
and it was not possible to remove it despite
pancreatic sphincterotomy and multiple at-
tempts. He is asymptomatic and without pseu-
docyst recurrence after a 29 month follow up.
Some authors had suggested that such complica-
tion doesn’t have any clinical consequence
[12,22]. Distal migration is more common,
doesn’t cause adverse effects and should not be
considered as a complication [22]. There was one
case ofmild pancreatitis that responded to clinical
measures as reported earlier [17, 22].DRAINAGE OF PSEUDOCYSTS 337
Pancreatic stents can induce MPD changes
like irregularities and strictures, and also
changes in secondary branches, similar those
changes found in chronic pancreatitis [19, 24].
They may be asymptomatic and reversible with
stent removal or exchange. We noticed morpho-
logic changes on pancreatic ducts after transpa-
pillary drainage in 2 cases, and both were
asymptomatic and had no recurrence. We
should keep in mind remind that such changes
can also be part of the natural history of chronic
pancreatitis.
Transmural drainage, mainly CG, presents
higher risk of complications, specially bleeding
[13,14,18]. We had 3 complications after CG
(bleeding, pneumoperitoneum and stent migra-
tion into the pseudocyst) and one after CD
(perforation). Asymptomatic pneumoperito-
neum was diagnosed one week after the
procedure during a routine CT. Possibly, it was
due to a small fistula during CG, maybe
secondary to the presence of ascites, even
though previous CT scan showed that the
distance between gastric wall and the pseudo-
cyst was less than lcm [25]. There was no
difference regarding the frequency of complica-
tions in the different Groups (Tab. II), although
both complications that needed surgery (bleed-
ing and duodenal perforation) occurred after
transmural drainage.
Endoscopic ultrasound (EUS) allows identifi-
cation of the best puncture site, specially in cases
without a clear gastroduodenal indentation,
besides identifying vascular structures between
gastric or duodenal wall and the pseudocyst
increasing effectiveness and safety of endoscopic
drainage [26, 27]. During the study EUS was not
available at our institution, and maybe both
complications that needed surgery (bleeding
and perforation) could be avoided, besides
allowing drainage in those cases in which we
were unable to identify gastroduodenal com-
pression. More recently we started to perform
EUS guided transmural drainage whenever
gastric or duodenal wall is not detected during
endoscopy [28]. Our success (pseudocyst regres-
sion) rate was similar to other published series
[12,14,17]. There was no difference among
different Groups, suggesting that drainage route
had no influence on the results.
Our recurrence rate was also comparable to
those reported by other authors [11,14]. The
only patient that presented pseudocyst recur-
rence was treated with another endoscopic
drainage, as already described [14, 18].
Comparative evaluation of abdominal pain
score before and after drainage showed statisti-
cally significant improvement. Asymptomatic
patients were mainly those in alcohol absti-
nence, and probably this an important factor for
good clinical response during long follow up.
In conclusion, we believe that pancreatic
pseudocyst endoscopic drainage is possible in
most patients, with high success rate and low
morbidity. Most complications can be clinically
and/or endoscopically managed. Transpapillary
drainage should be tried before transmural
drainage, because it is associated with low
morbidity. Patients that are successfully drained
have important clinical improvement and recur-
rence is uncommon, specially for those that stay
in alcohol abstinence.
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